Prilocaine and hydrofluourocarbon aerosol preparations
Patent 5589156 Issued on December 31, 1996. Estimated Expiration Date: 
May 5, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 5, 2015. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 5118494 Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content Medicinal aerosol formulations Vision aid and anesthetic composition Topical composition enhancing healing of viral lesions Patent #: 5380754 InventorApplicationNo. 435812 filed on 05/05/1995US Classes:424/45, Organic pressurized fluid424/46, Powder or dust containing424/47, Topical live body grooming or adorning aid (e.g., hair spray, antiperspirant, etc.)514/818, ANESTHETIC, LOCAL514/974CONTAINING DESIGNATED INGREDIENT TO REDUCE NOXIOUS EFFECTS OF ACTIVE INGREDIENT (E.G., TASTE MASKING, ODOR REDUCING, ETC.)ExaminersPrimary: Bawa, RajAttorney, Agent or FirmForeign Patent References
International ClassA61K 009/12AbstractAerosol compositions used for anesthetizing mammals in both human and veterinary applications include prilocaine base solubilized in the hydrofluorocarbon (HFC) propellants 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane. Prilocaine base has been found to be readily soluble in HFC propellants when combined in liquid or micro rod form, and a solution stable to temperatures as low as -82° C. is formed upon combination of the two components. In the aerosol compositions, the HFCs are the only propellants used. Additional pharmaceutical constituents can also be combined the the prilocaine base/HFC composition to provide a multi-component anesthetic, and it has been found that the presence of prilocaine in the combination can assist in solubilizing and/or suspending these pharmaceutical consituents. Some example pharmaceutical compositions within the practice of this invention include HFC, prilocaine base, and a pharmaceutical other prilocaine selected from the group consisting of bronchodilators, antiinflammatories, antitusives, vasoactive drugs, vasoconstrictors, antibiotics, peptides, steroids, enzymes, antihistamines, hormones, enzyme and receptor inhibitors and agonists, 5-aminolevulinic acid, antiseptics, disinfectants, procaine, cocaine, chloroprocaine, tetractaine, mepivacaine, lidocaine, bupivacaine, etidocaine, ropivacaine, benzocaine, and phenylephrine.Other References
| |
